Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "ophthalmology"

116 News Found

Axol Bioscience acquires ophthalmology business from Newcells Biotech
News | February 19, 2026

Axol Bioscience acquires ophthalmology business from Newcells Biotech

Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models


Nethradhama’s conference on ophthalmology sees launch of advanced eye care technologies
News | January 16, 2024

Nethradhama’s conference on ophthalmology sees launch of advanced eye care technologies

The three-day event in Bengaluru was conducted in collaboration with the Karnataka Ophthalmology Society (KOS) and the Bangalore Ophthalmology Society (BOS)


Alkem forays into ophthalmology with launch of eye care products
News | July 07, 2023

Alkem forays into ophthalmology with launch of eye care products

Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc


GUERISON enters Indian Ophthalmology market
News | February 17, 2023

GUERISON enters Indian Ophthalmology market

The company has launched its new range of 25 allopathy ophthalmic products including GUERIMOD, GUERIPRED, BIMATO MST etc. for curing various diseases related to eyes


Guerison to set up footprints in India’s ophthalmology market
News | December 20, 2022

Guerison to set up footprints in India’s ophthalmology market

Global pharmaceutical company having a surgical business concept incepted in Dubai


Eye-Q upgrades advanced affordable eye care facility in Lucknow
Hospitals | May 09, 2026

Eye-Q upgrades advanced affordable eye care facility in Lucknow

The upgraded Rajajipuram centre now features enhanced retina services and advanced OCT technology


Bayer strikes $2.45 billion deal for breakthrough blindness drug developer Perfuse Therapeutics
News | May 07, 2026

Bayer strikes $2.45 billion deal for breakthrough blindness drug developer Perfuse Therapeutics

The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy